UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 16, 2015
LEXARIA CORP.
(Exact name of
registrant as specified in its charter)
Nevada | 000-52138 | 20-2000871 |
(State or other jurisdiction of | (Commission File Number) | (IRS Employer |
incorporation) | Identification No.) |
#950 1130 West Pender Street, Vancouver, BC Canada | V6E 4A4 |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code (604) 602-1675
N/A
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d -2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e
-4(c))
2
Item 5.03 Amendments to Articles of Incorporation or Bylaws
Item 8.01 Other Items
On November 24, 2015, our board of directors approved a forward stock split of our authorized and issued and outstanding shares of common stock on a basis of 1 old share of common stock for 1.1 new shares of common stock. Upon effect of the forward stock split our authorized capital will increase 220,000,000 shares of common stock, par value $0.001 and our issued and outstanding shares will increase from 39,952,984 to 43,948,286 shares of common stock, with a par value of $0.001.
The reverse stock split has been reviewed by the Financial Industry Regulatory Authority ("FINRA") and the Canadian Securities Exchange ("CSE") have been approved for filing with an effective date of December 16, 2015.
The forward split will become effective with the OTC Markets at the opening of trading on December 16, 205 under the symbol LXRPD. The "D" will be placed on our ticker symbol for 20 business days. Our new CUSIP number is 52886N307.
Item 7.01 Regulation FD Disclosure.
A copy of the news release announcing Lexaria announcing forward split filed as exhibit 99.1 to this current report and is hereby incorporated by reference.
Item 9.01 Financial Statements and Exhibits
3.1 | |
99.1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LEXARIA CORP.
____________________
Chris Bunka
CEO
Date: December 16, 2015
Lexaria Forward Stock Split
KELOWNA, BC-- December 16, 2015 - Lexaria Corp. (OTCQB: LXRPD) (CNSX: LXX) (the "Company" or "Lexaria") confirms the earlier announced Lexaria forward stock split has taken place and the companys shares begin trading on a post-split basis today at the open of trading.
On November 24, 2015, our board of directors approved a forward stock split of our authorized and issued and outstanding shares of common stock on a basis of 1 old share of common stock for 1.1 new shares of common stock. Upon effect of the forward stock split our authorized capital will increase to 220,000,000 shares of common stock, par value $0.001.
The reverse stock split has been reviewed by the Financial Industry Regulatory Authority ("FINRA") and the Canadian Securities Exchange ("CSE") and has been approved for filing with an effective date of December 16, 2015. The Companys trading symbol on the Canadian Securities Exchange remains unchanged: LXX.
The forward split is effective with the OTC Markets at the opening of trading on December 16, 2015 under the symbol LXRPD. The "D" will be placed on our ticker symbol for 20 business days, and then the trading symbol will revert back to LXRP. Our new CUSIP number is 52886N307.
Lexaria thanks its shareholders for their continued support and will in the future provide information at an appropriate time if our board of directors should decide at some point in the future to once again effect a forward stock split of the companys shares.
About Lexaria
Lexaria is a food sciences company, with common shares quoted in the USA with symbol LXRP and in Canada with symbol LXX. The Company uses innovative technology to deliver unique food experiences. www.lexarienergy.com
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria
Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: the provision of any significant investor relations or media relations services. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the medical marijuana, hemp oil sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company's needs or that it will not need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any hemp oil or cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. There is no assurance that the cannabinoid/lipid infusion technology will provide any increase in bioavailability to any individual person. There is no assurance that any patent application in the USA or any other nation or under any treaty will result in the award of an actual patent; nor that an award of any actual patent will protect against challenges from unknown third parties. There is no assurance that any of Lexarias postulated uses, benefits, or advantages for the patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova TM products and Lexaria Energy products are not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.